This page shows the latest natalizumab news and features for those working in and with pharma, biotech and healthcare.
Despite the setback, Novartis is continuing to expand its generics division, with natalizumab its fifth proposed biosimilar in nine months.
remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).
for Biogen's Tysabri (natalizumab) and Novartis' Gilenya (fingolimod).
After years of disappointing trials in SPMS - most recently the failure of Biogen's Tysabri (natalizumab) - there are finally some optimistic signs that patients with progressive forms of MS could get
Among the pipeline casualties are Tecfidera for secondary progressive MS, and Biogen also reported yesterday that its injectable MS drug Tysabri (natalizumab) was unable to slow disability progression in this
Biogen's rise is predominately due to its growing share of the multiple sclerosis (MS) market, with strong sales for its established medicine Tsyabri(natalizumab) and more recent launches of two
More from news
Approximately 4 fully matching, plus 48 partially matching documents found.
The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.
He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Lemtrada is a monoclonal antibody (MAB) given by infusion. Tysabri, or natalizumab, is also an infusion injection.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...